RxDoctor Payments Data

Rashid Baghai-Naini, MD

Internal Medicine · Silver Spring, MDNPI 1366479339

Payments from drug & device makers

$3,012in general payments, 2019–2025

Across 151 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$896
  • Lilly USA, LLC$394
  • GSK$364
  • Novo Nordisk$278
  • AstraZeneca$277
  • Boehringer Ingelheim$230
  • plus $573 from 9 others

What the payments were for

  • Food & beverage$3,012100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,012 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$112,913
Medicare patients
175
Services billed
1,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$91,317
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog62$29,055
JanuviaSitagliptin Phosphate15$18,368
JardianceEmpagliflozin23$17,264
TradjentaLinagliptin16$11,831
Breo ElliptaFluticasone/Vilanterol22$9,066
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,448
Atorvastatin Calcium200$1,370
Losartan Potassium128$1,171
Amlodipine Besylate225$1,090
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic19$1,043
Enalapril Maleate19$1,000
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$824
Omeprazole71$804
Simvastatin76$797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$278$91,31780 claims
Boehringer IngelheimJardiance, Tradjenta$230$29,09439 claims
GSKBreo Ellipta, Anoro Ellipta$364$16,51538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →